Jump to content

Missense mutation

From Wikipedia, the free encyclopedia
(Redirected from Missense mutations)

In genetics, a missense mutation is a point mutation in which a single nucleotide change results in a codon that codes for a different amino acid.[1] It is a type of nonsynonymous substitution. Missense mutations change amino acids, which in turn alter proteins and often their function or structure[2]. These mutations can arise spontaneously from mutagens like UV radiation[3], tobacco smoke[4], error in DNA replication[5], and other factors. Screening for missense mutations can be done by sequencing the genome of an organism and comparing to a reference genome to analyze for differences. Missense mutations can be repaired by the cell when there are errors in DNA replication, using mechanisms like mismatch repair. They can also be repaired by using genetic engineering technologies or pharmaceuticals. Some notable examples of human diseases caused by missense mutations are Rett syndrome[6] and sickle-cell disease[7].

Impact on protein function

[edit]
This image shows an example of missense mutation. One of the nucleotides (adenine) is replaced by another nucleotide (cytosine) in the DNA sequence. This results in an incorrect amino acid (proline) being incorporated into the protein sequence.

Missense mutation refers to a change in one amino acid in a protein arising from a point mutation in a single nucleotide. Amino acid's are the building blocks of proteins. Missense mutations are a type of nonsynonymous substitution in a DNA sequence. Two other types of nonsynonymous substitutions are the nonsense mutations, in which a codon is changed to a premature stop codon that results in the resulting protein being cut short, and the nonstop mutations, in which a stop codon deletion results in a longer but nonfunctional protein.

Missense mutations can render the resulting protein nonfunctional,[2] due to misfolding of the protein,[8] and these mutations are responsible for human diseases such as Epidermolysis bullosa,[9] sickle-cell disease[10] SOD1 mediated ALS, and a substantial number of cancers.[11][12]

Not all missense mutations lead to appreciable protein changes. An amino acid may be replaced by an amino acid of very similar chemical properties, in which case, the protein may still function normally; this is termed a neutral, "quiet", "silent" or conservative mutation. Alternatively, the amino acid substitution could occur in a region of the protein which does not significantly affect the protein secondary structure or function. When an amino acid may be encoded by more than one codon (so-called "degenerate coding") a mutation in a codon may not produce any change in translation; this would be a synonymous substitution and not a missense mutation.

Causes

[edit]

Missense mutations may be inherited or arise spontaneously, termed de novo mutations[13]. Well studied diseases arising from inherited missense mutations, include sickle cell anemia[14], cystic fibrosis[15], and early-onset Alzheimer's[16] and Parkinson's disease[17]. De novo mutations that increase or decrease the activity of synapses have been implicated in the development of neurological and developmental disorders[18], such a Autism Spectrum Disorder[18] and intellectual delay[13].

Agents of Spontaneous Missense Mutation

[edit]

Environmental mutagens, such as tobacco smoke or UV radiation, may be a cause of spontaneous missense mutations[4][3]. Tobacco smoke has been implicated in transversion mutations in the KRAS gene, with a meta-analysis of lung carcinomas showing 25 tumours containing a G to T mutation (changing codon GGT to TGT), causing an amino acid change from glycine to cysteine, and 11 tumours with a G to T mutation (changing codon GGT to GTG), causing an amino acid change from glycine to valine[4]. Similarly, numerous studies have shown ultraviolet light induces missense mutations in the p53 gene[3][19],  which when unregulated, reduces the cell's ability to recognize DNA damage and engage in apoptosis, leading to cell proliferation and potential skin carcinogenesis[3].

DNA polymerase replication errors during cell division may lead to spontaneous missense mutations, if DNA polymerase's proofreading ability does not detect and repair an error it makes[13]. Spontaneous DNA polymerase errors are estimated to occur 1/10^9 base pairs[13].

Although rarer, tautomerization of bases also creates spontaneous missense mutations. Tautomerization means that the hydrogen atoms on DNA bases, can spontaneously change locations, impacting the structure of the base, and allowing it to pair with an incorrect base[20]. If this strand of DNA is replicated, the incorrect base will be the template for a new strand, leading to a mutation, possibly changing the amino acid and therefore, the protein[5]. For example, Wang et al., (2011) used X-ray cystallography to demonstrate that a de novo mutation was created when DNA repair mechanisms did not recognize a C-A base mismatch, due to tautomerization allowing the base structures to be compatible[21].

Screening

[edit]

Next Generation Sequencing (NGS)

[edit]

Next Generation Sequencing (NGS) utilizes massively parallel sequencing to sequence the genome. This involves clonally amplified DNA fragments that can be spatially separated into second generation sequencing (SGS) or third generation sequencing (TGS) platforms.[22] Using massively parallel sequencing allows the NGS platform to produce very large sequences in a single run.[23] The DNA fragments are typically separated by length using gel electrophoresis.

NGS consists of four main steps, DNA isolation, target enrichment, sequencing, and data analysis.[23] The DNA isolation step involves breaking the genomic DNA into many small fragments. There are many different mechanisms that can be used to accomplish this such as mechanical methods, enzymatic digestion, and more.[24] This step also consists of adding adaptors to either end of the DNA fragments that are complementary to the flow cell oligos and include primer binding sites for the target DNA. The target enrichment step amplifies the region of interest. This includes creating a complementary strand to the DNA fragments through hybridization to a flow cell oligo. It then gets denatured and bridge amplification occurs before the reverse strand is finally washed and sequencing can occur. The sequencing step involves massive parallel sequencing of all DNA fragments simultaneously using a NGS sequencer. This information is saved and analyzed in the last step, data analysis, using bioinformatics software. This compares the sequences to a reference genome to align the fragments and show mutations in the targeted area of the sequence.[24]

Newborn Screening (NBS)

[edit]

Newborn screening (NBS) for missense mutations is increasingly incorporating genomic technologies in addition to traditional biochemical methods to improve the detection of genetic disorders early in life. Traditional NBS primarily relies on biochemical assays, such as tandem mass spectrometry[25], to detect metabolic abnormalities indicative of conditions like phenylketonuria or congenital hypothyroidism.[26] However, these methods may miss genetic causes or produce ambiguous results. To address these deficiencies, next-generation sequencing (NGS) is being added to NBS programs.[27] For instance, targeted gene panels and whole-exome sequencing (WES) are used to identify disease causing missense mutations in genes associated with treatable conditions, such as severe combined immunodeficiency (SCID) and cystic fibrosis. Studies like the BabyDetect project have demonstrated the utility of genomic screening in identifying disorders missed by conventional methods, with actionable results for conditions affecting more than 400 genes.[28][29] In addition, genomic approaches allow for the detection of rare or recessive conditions that may not manifest biochemically at birth, significantly expanding the scope of diseases screened.[30] These advancements align with the established principles of NBS, which emphasize early detection and intervention to prevent morbidity and mortality.[31]

Prevention and repair mechanisms

[edit]

Cellular mechanisms

[edit]

DNA polymerases, used in DNA replication, have a high specificity of 104 to 106-fold, in base pairing.[32] In the base mismatches that occur, 90 to 99.9% are repaired by the DNA mismatch repair pathway, inherent in cells.[32][33][34] The DNA mismatch repair pathway uses exonucleases, that move along the DNA strand and remove the incorrectly incorporated base, in order for DNA polymerase to fill in the correct base. Exonuclease1 is involved in many DNA repair systems and moves 5' to 3' on the DNA strand.[35]

Genetic engineering and drug-based interventions

[edit]

More recently, research has explored the use of genetic engineering[36] and pharmaceuticals as potential treatments.[37][38] tRNA therapies have emerged in research studies as a potential missense mutation treatment, following evidence supporting their use in nonsense mutation correction.[39] Missense-correcting tRNAs are engineered to identify the mutated codon, but carry the correct charged amino acid, which is inserted into the nascent protein.[36] Pharmaceuticals that target specific proteins affected by missense mutations, have also shown therapeutic potential.[37][38] Pharmaceutical studies have particularly focused on targeting the p53 mutant protein and Ca^2+ channel abnormalities, both caused by gain of function missense mutations, due to their high prevalence in a number of cancers and genetic diseases respectively.[38][39]

Evolution

[edit]
Diverged nucleotide sequence demonstrating how sequences diverge over time. Red letters are nucleotides changed from the original sequence.

If a missense mutation is not deleterious, it will not be selected against and can contribute to species divergence.[40] Over time, mutations occur randomly in individuals and can become fixed in populations if they are not selected against.[41] Missense mutations are a type of mutation that are not neutral, and therefore can be acted on by selection. Selection could not act on synonymous mutations (mutations that do not change anything phenotypically).[42]

Tracking missense mutations, like SNPs, in ancestral species populations allow genealogies and phylogenetic trees to be created and evolutionary connections to be made. Missense mutation analysis is often used in evolutionary genetics to create relationships between species, as amino acid changes leading to protein changes are needed for species to diverge from each other.

Notable examples

[edit]

LMNA

[edit]
Wild type (left) and mutated (right) form of lamin A (pdb id: 1IFR). Normally, Arginine 527 (blue) forms salt bridge with glutamate 537 (magenta), but R527L substitution results in breaking this interaction (leucine has a nonpolar tail and therefore cannot form a static salt bridge).
    DNA: 5' - AAC AGC CTG CGT ACG GCT CTC - 3'
         3' - TTG TCG GAC GCA TGC CGA GAG - 5'
   mRNA: 5' - AAC AGC CUG CGU ACG GCU CUC - 3'
Protein:      Asn Ser Leu Arg Thr Ala Leu

LMNA missense mutation (c.1580G>T) introduced at LMNA gene – position 1580 (nt) in the DNA sequence (CGT) causing the guanine to be replaced with the thymine, yielding CTT in the DNA sequence. This results at the protein level in the replacement of the arginine by the leucine at the position 527.[43] This leads to destruction of salt bridge and structure destabilization. At phenotype level this manifests with overlapping mandibuloacral dysplasia and progeria syndrome.

The resulting transcript and protein product is: 

    DNA: 5' - AAC AGC CTG CTT ACG GCT CTC - 3'
         3' - TTG TCG GAC GAA TGC CGA GAG - 5'
   mRNA: 5' - AAC AGC CUG CUU ACG GCU CUC - 3'
Protein:      Asn Ser Leu Leu Thr Ala Leu

Rett Syndrome

[edit]

Missense mutations in the MeCP2 protein can cause Rett syndrome, otherwise known as the RTT phenotype.[44] T158M, R306C and R133C are the most common missense mutations causing RTT.[44] T158M is a mutation of an adenine being substituted for a guanine causing the threonine at amino acid position 158 being substituted with a methionine.[45] R133C is a mutation of a cytosine at base position 417 in the gene encoding the MeCP2 protein being substituted for a thymine, causing an amino acid substitution at position 133 in the protein of arginine with cysteine.[6]

Sickle Cell

[edit]
(1) Normal red blood cells and (2) sickled-cell red blood cells

Sickle-cell disease changes the shape of red blood cells from round to sickle shaped.[46] In the most common variant of sickle-cell disease, the 20th nucleotide of the gene for the beta chain of hemoglobin is altered from the codon GAG to GTG. Thus, the 6th amino acid, glutamic acid, is substituted by valine—notated as an "E6V" or a "Glu6Val" mutation—which causes the protein to be sufficiently altered with a sickle-cell phenotype.[47] The affected cells cause issues in the bloodstream as they can become sticky due to their improper ion transport causing them to be susceptible to water loss.[7] This can cause a buildup of blood cells that obstructs blood flow to any organ in the body.[7]

Other conditions that can be caused by missense mutations

[edit]

See also

[edit]

References

[edit]
  1. ^ "Definition of Missense mutation". MedTerms medical dictionary. MedicineNet. 2012-03-19. Archived from the original on 2013-12-02. Retrieved 2011-09-08.
  2. ^ a b Minde DP, Anvarian Z, Rüdiger SG, Maurice MM (August 2011). "Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?". Molecular Cancer. 10 (1): 101. doi:10.1186/1476-4598-10-101. PMC 3170638. PMID 21859464.
  3. ^ a b c d Carvalho C, Silva R, Melo TM, Inga A, Saraiva L (2024-11-27). "P53 and the Ultraviolet Radiation-Induced Skin Response: Finding the Light in the Darkness of Triggered Carcinogenesis". Cancers. 16 (23): 3978. doi:10.3390/cancers16233978. ISSN 2072-6694. PMC 11640378. PMID 39682165.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ a b c Ahrendt SA, Decker PA, Alawi EA, Zhu Yr, Sanchez-Cespedes M, Yang SC, et al. (2001-09-15). "Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung". Cancer. 92 (6): 1525–1530. doi:10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H.
  5. ^ a b Shen CH (2023-01-01), Shen CH (ed.), "Chapter 2 - Nucleic acid-based cellular activities – DNA replication, damage, and repair", Diagnostic Molecular Biology (Second Edition), Academic Press, pp. 27–56, doi:10.1016/b978-0-323-91788-9.00009-0, ISBN 978-0-323-91788-9, retrieved 2025-03-21
  6. ^ a b Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (October 1999). "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2". Nature Genetics. 23 (2): 185–188. doi:10.1038/13810. PMID 10508514.
  7. ^ a b c Parker JC, Orringer EP (1990-04-27). "Sickle Cell Disease. Charles F. Whrrren and John F. Bertles, Eds. New York Academy of Sciences, New York, 1989. xiv, 477 pp., illus. $119. Annals of the New York Academy of Sciences, vol. 565. From a conference, Bethesda, MD, April 1988". Science. 248 (4954): 502. doi:10.1126/science.248.4954.502. ISSN 0036-8075.
  8. ^ a b c d e Stefl S, Nishi H, Petukh M, Panchenko AR, Alexov E (November 2013). "Molecular mechanisms of disease-causing missense mutations". Journal of Molecular Biology. 425 (21): 3919–3936. doi:10.1016/j.jmb.2013.07.014. PMC 3796015. PMID 23871686.
  9. ^ Miura Y, Nakagomi S (September 2021). "Management of Cutaneous Manifestations of Genetic Epidermolysis Bullosa: A Multiple Case Series". Journal of Wound, Ostomy, and Continence Nursing. 48 (5): 453–459. doi:10.1097/WON.0000000000000784. PMID 34495939.
  10. ^ Piel FB, Steinberg MH, Rees DC (April 2017). Longo DL (ed.). "Sickle Cell Disease". The New England Journal of Medicine. 376 (16): 1561–1573. doi:10.1056/NEJMra1510865. PMID 28423290.
  11. ^ Boillée S, Vande Velde C, Cleveland DW (October 2006). "ALS: a disease of motor neurons and their nonneuronal neighbors". Neuron. 52 (1): 39–59. doi:10.1016/j.neuron.2006.09.018. PMID 17015226.
  12. ^ Henderson M (May 1, 2020). "A Monumental Breakthrough?". The News-Star. pp. A1, A7. Retrieved 21 November 2022.
  13. ^ a b c d Al Aboud NM, Basit H, Al-Jindan FA (2025), "Genetics, DNA Damage and Repair", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31082132, retrieved 2025-03-21
  14. ^ Tsukahara K, Chang X, Mentch F, Smith-Whitley K, Bhandari A, Norris C, et al. (2024-08-29). "Identification of genetic variants associated with clinical features of sickle cell disease". Scientific Reports. 14 (1). doi:10.1038/s41598-024-70922-5. ISSN 2045-2322. PMC 11362596. PMID 39209956.
  15. ^ Serre J.L. (a, b), Mornet E. (b, c), Simon-Bouy B. (b, c), Boué J(, Boué A( (1993). "General Cystic Fibrosis Mutations Are Usually Missense Mutations Affecting Two Specific Protein Domains and Associated with a Specific RFLP Marker Haplotype". European Journal of Human Genetics. 1 (4): 287–295. doi:10.1159/000472426. ISSN 1018-4813.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Hoogmartens J, Hens E, Engelborghs S, Vandenberghe R, De Deyn PP, Cacace R, et al. (March 2021). "Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease". Neurobiology of Aging. 99: 100.e17–100.e23. doi:10.1016/j.neurobiolaging.2020.09.009.
  17. ^ Cooper C, Goldman J, Zabetian C, Mata I, Leverenz J (2019-04-09). "SNCA G51D Missense Mutation Causing Juvenile Onset Parkinson's Disease (P5.8-026)". Neurology. 92 (15_supplement). doi:10.1212/WNL.92.15_supplement.P5.8-026. ISSN 0028-3878.
  18. ^ a b Geisheker MR, Heymann G, Wang T, Coe BP, Turner TN, Stessman HA, et al. (2017-08-01). "Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains". Nature Neuroscience. 20 (8): 1043–1051. doi:10.1038/nn.4589. ISSN 1097-6256. PMC 5539915. PMID 28628100.
  19. ^ Huang XX, Bernerd F, Halliday GM (April 2009). "Ultraviolet A within Sunlight Induces Mutations in the Epidermal Basal Layer of Engineered Human Skin". The American Journal of Pathology. 174 (4): 1534–1543. doi:10.2353/ajpath.2009.080318. PMC 2671383. PMID 19264911.
  20. ^ Shen CH (2023-01-01), Shen CH (ed.), "Chapter 1 - Nucleic acids: DNA and RNA", Diagnostic Molecular Biology (Second Edition), Academic Press, pp. 1–26, doi:10.1016/b978-0-323-91788-9.00005-3, ISBN 978-0-323-91788-9, retrieved 2025-03-21
  21. ^ Wang W, Hellinga HW, Beese LS (2011-10-25). "Structural evidence for the rare tautomer hypothesis of spontaneous mutagenesis". Proceedings of the National Academy of Sciences. 108 (43): 17644–17648. doi:10.1073/pnas.1114496108. ISSN 0027-8424. PMC 3203791. PMID 22006298.
  22. ^ Xu J (2014). Next-generation sequencing: current technologies and applicaitons. Norfolk: Caister academic press. ISBN 978-1-908230-33-1.
  23. ^ a b Valencia CA, Pervaiz MA, Husami A, Qian Y, Zhang K (2013). Next Generation Sequencing Technologies in Medical Genetics. SpringerBriefs in Genetics. New York, NY: Springer New York. doi:10.1007/978-1-4614-9032-6. ISBN 978-1-4614-9031-9.
  24. ^ a b Qin D (February 2019). "Next-generation sequencing and its clinical application". Cancer Biology & Medicine. 16 (1): 4–10. doi:10.20892/j.issn.2095-3941.2018.0055. PMC 6528456. PMID 31119042.
  25. ^ Levy HL (1998-12-01). "Newborn Screening by Tandem Mass Spectrometry: A New Era". Clinical Chemistry. 44 (12): 2401–2402. doi:10.1093/clinchem/44.12.2401. ISSN 0009-9147.
  26. ^ Cunningham G (2002-04-04). "The Science and Politics of Screening Newborns". New England Journal of Medicine. 346 (14): 1084–1085. doi:10.1056/NEJM200204043461411. ISSN 0028-4793.
  27. ^ Remec ZI, Trebusak Podkrajsek K, Repic Lampret B, Kovac J, Groselj U, Tesovnik T, et al. (2021-05-26). "Next-Generation Sequencing in Newborn Screening: A Review of Current State". Frontiers in Genetics. 12. doi:10.3389/fgene.2021.662254. ISSN 1664-8021. PMC 8188483. PMID 34122514.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  28. ^ Boemer F, Hovhannesyan K, Piazzon F, Minner F, Mni M, Jacquemin V, et al. (January 2025). "Population-based, first-tier genomic newborn screening in the maternity ward". Nature Medicine. doi:10.1038/s41591-024-03465-x. PMID 39875687.
  29. ^ Rai P, Mamcarz EK, Hankins JS (2021). "Newborn Genetic Screening for Blood Disorders". In de Alarcón PA, Werner EJ, Christensen RD (eds.). Neonatal Hematology: Pathogenesis, Diagnosis, and Management of Hematologic Problems (3rd ed.). Cambridge: Cambridge University Press. ISBN 978-1-108-48898-3.
  30. ^ Jiang S, Wang H, Gu Y (September 2023). "Genome Sequencing for Newborn Screening-An Effective Approach for Tackling Rare Diseases". JAMA Network Open. 6 (9): e2331141. doi:10.1001/jamanetworkopen.2023.31141. PMID 37656463.
  31. ^ Clarke JT (2005). "Newborn screening.". A Clinical Guide to Inherited Metabolic Diseases. Cambridge: Cambridge University Press. pp. 228–240. doi:10.1017/CBO9780511544682.011. ISBN 978-0-511-54468-2.
  32. ^ a b Kunkel TA (April 2004). "DNA replication fidelity". The Journal of Biological Chemistry. 279 (17): 16895–16898. doi:10.1074/jbc.R400006200. PMID 14988392.
  33. ^ Li GM (January 2008). "Mechanisms and functions of DNA mismatch repair". Cell Research. 18 (1): 85–98. doi:10.1038/cr.2007.115. PMID 18157157.
  34. ^ Kunkel TA, Erie DA (2005-06-01). "DNA mismatch repair". Annual Review of Biochemistry. 74 (1): 681–710. doi:10.1146/annurev.biochem.74.082803.133243. PMID 15952900.
  35. ^ Goellner EM, Putnam CD, Kolodner RD (August 2015). "Exonuclease 1-dependent and independent mismatch repair". DNA Repair. 32: 24–32. doi:10.1016/j.dnarep.2015.04.010. PMC 4522362. PMID 25956862.
  36. ^ a b Hou Y, Zhang W, McGilvray PT, Sobczyk M, Wang T, Weng SH, et al. (February 2024). "Engineered mischarged transfer RNAs for correcting pathogenic missense mutations". Molecular Therapy. 32 (2): 352–371. doi:10.1016/j.ymthe.2023.12.014. PMC 10861979. PMID 38104240.
  37. ^ a b Striessnig J (2021-03-03). "Voltage-Gated Ca2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies". Frontiers in Synaptic Neuroscience. 13: 634760. doi:10.3389/fnsyn.2021.634760. PMC 7966529. PMID 33746731.
  38. ^ a b c Schulz-Heddergott R, Moll UM (June 2018). "Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target". Cancers. 10 (6): 188. doi:10.3390/cancers10060188. PMC 6025530. PMID 29875343.
  39. ^ a b Albers S, Beckert B, Matthies MC, Mandava CS, Schuster R, Seuring C, et al. (June 2021). "Repurposing tRNAs for nonsense suppression". Nature Communications. 12 (1): 3850. Bibcode:2021NatCo..12.3850A. doi:10.1038/s41467-021-24076-x. PMC 8219837. PMID 34158503.
  40. ^ Kryukov GV, Pennacchio LA, Sunyaev SR (April 2007). "Most Rare Missense Alleles Are Deleterious in Humans: Implications for Complex Disease and Association Studies". The American Journal of Human Genetics. 80 (4): 727–739. doi:10.1086/513473. PMC 1852724. PMID 17357078.
  41. ^ Zhang G, Pei Z, Krawczak M, Ball EV, Mort M, Kehrer-Sawatzki H, et al. (December 2010). "Triangulation of the human, chimpanzee, and Neanderthal genome sequences identifies potentially compensated mutations". Human Mutation. 31 (12): 1286–1293. doi:10.1002/humu.21389. PMID 21064102.
  42. ^ Shen X, Song S, Li C, Zhang J (2022-06-23). "Synonymous mutations in representative yeast genes are mostly strongly non-neutral". Nature. 606 (7915): 725–731. Bibcode:2022Natur.606..725S. doi:10.1038/s41586-022-04823-w. ISSN 0028-0836. PMC 9650438. PMID 35676473.
  43. ^ Al-Haggar M, Madej-Pilarczyk A, Kozlowski L, Bujnicki JM, Yahia S, Abdel-Hadi D, et al. (November 2012). "A novel homozygous p.Arg527Leu LMNA mutation in two unrelated Egyptian families causes overlapping mandibuloacral dysplasia and progeria syndrome". European Journal of Human Genetics. 20 (11): 1134–1140. doi:10.1038/ejhg.2012.77. PMC 3476705. PMID 22549407.
  44. ^ a b Brown K, Selfridge J, Lagger S, Connelly J, De Sousa D, Kerr A, et al. (February 2016). "The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome". Human Molecular Genetics. 25 (3): 558–570. doi:10.1093/hmg/ddv496. PMC 4731022. PMID 26647311.
  45. ^ Zhou Z, Goffin D (2014). "Modeling Rett Syndrome with MeCP2 T158A Knockin Mice". In Patel VB, Preedy VR, Martin CR (eds.). Comprehensive Guide to Autism. New York, NY: Springer New York. pp. 2723–2739. doi:10.1007/978-1-4614-4788-7_181. ISBN 978-1-4614-4787-0. Retrieved 2025-02-07.
  46. ^ Esoh K, Wonkam A (2021-03-01). "Evolutionary history of sickle-cell mutation: implications for global genetic medicine". Human Molecular Genetics. 30 (R1): R119 – R128. doi:10.1093/hmg/ddab004. ISSN 0964-6906. PMC 8117455. PMID 33461216.
  47. ^ "141900 Hemoglobin—Beta Locus; HBB: .0243 Hemoglobin S. Sickle Cell Anemia, included. Malaria, Resistance to, included. HBB, GLU6VAL — 141900.0243". Online 'Mendelian Inheritance in Man' (OMIM).
  48. ^ Yang L, Yu P, Chen X, Cai T (August 2016). "The de novo missense mutation N117S in skeletal muscle α-actin 1 causes a mild form of congenital nemaline myopathy". Molecular Medicine Reports. 14 (2): 1693–1696. doi:10.3892/mmr.2016.5429. ISSN 1791-2997. PMID 27357517.
[edit]
Wikimedia Commons has media related to Missense mutation.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Missense_mutation&oldid=1281645102"